| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043147565 |
| P356 | DOI | 10.1038/SJ.BMT.1705758 |
| P698 | PubMed publication ID | 17603513 |
| P5875 | ResearchGate publication ID | 6233153 |
| P2093 | author name string | Lazarus HM | |
| Batts ED | |||
| P2860 | cites work | Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family | Q24291639 |
| Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura | Q24291691 | ||
| Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura | Q24614077 | ||
| Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | Q24685473 | ||
| Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy: a report of a case and a review of the literature | Q28340459 | ||
| The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injury in vivo. | Q33243521 | ||
| Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. | Q33256286 | ||
| Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children | Q33330262 | ||
| Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement | Q33330718 | ||
| A case of hemolytic uremic syndrome improved with nitric oxide | Q33331348 | ||
| Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome | Q33333765 | ||
| Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities | Q33335306 | ||
| Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation | Q33335309 | ||
| Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease | Q33335807 | ||
| Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes | Q33337015 | ||
| The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. | Q33337105 | ||
| Partial amino acid sequence of purified von Willebrand factor-cleaving protease | Q33338825 | ||
| Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura | Q33339170 | ||
| Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy | Q33341756 | ||
| Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation | Q33342975 | ||
| Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). | Q33343954 | ||
| Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver | Q33344003 | ||
| Transplantation-associated thrombotic microangiopathy: twenty-two years later | Q33345369 | ||
| Thrombotic thrombocytopenic purpura following stem cell transplantation | Q33345682 | ||
| ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients | Q33346954 | ||
| Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review | Q33347394 | ||
| Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation | Q33357738 | ||
| Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma | Q33359551 | ||
| Recent advances in thrombotic thrombocytopenic purpura | Q33363823 | ||
| The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine | Q33366493 | ||
| Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation | Q33366697 | ||
| Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q33366979 | ||
| Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation | Q33367451 | ||
| Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. | Q33368614 | ||
| Thrombotic microangiopathy in transplantation and malignancy | Q33369772 | ||
| von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation | Q33370723 | ||
| Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation | Q33371965 | ||
| Thrombotic thrombocytopenic purpura: a moving target | Q33373379 | ||
| Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group | Q33373889 | ||
| Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. | Q33487554 | ||
| Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group | Q33496619 | ||
| Apheresis in grade 4 bone marrow transplant associated thrombotic microangiopathy: a case series | Q33498152 | ||
| Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignancies | Q33501821 | ||
| Thrombotic microangiopathy of hyperacute onset after autologous peripheral blood stem cell transplantation in malignant lymphoma. | Q33503102 | ||
| Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis | Q33503480 | ||
| von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome | Q33504463 | ||
| Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer | Q36447619 | ||
| Procoagulant microparticles: disrupting the vascular homeostasis equation? | Q36600785 | ||
| Defibrotide Protects Endothelial Cells, but not L929 Tumour Cells, from Tumour Necrosis Factor-α-mediated Cytotoxicity | Q41366506 | ||
| Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angiopl | Q43446003 | ||
| Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome | Q43834946 | ||
| Oral eicosapentaenoic acid for complications of bone marrow transplantation | Q43848102 | ||
| Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats | Q44136581 | ||
| Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome | Q44189562 | ||
| Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients | Q44227097 | ||
| Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. | Q44272977 | ||
| Endothelial damage caused by cytomegalovirus and human herpesvirus-6. | Q44383243 | ||
| Amelioration of cyclosporin A effect on microvasculature by endothelin inhibitor | Q44567965 | ||
| Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination | Q44899011 | ||
| Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced | Q44943026 | ||
| Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. | Q45172538 | ||
| The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans | Q45194890 | ||
| Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results | Q45256819 | ||
| The pathology of ionizing radiation as defined by morphologic patterns. | Q45949439 | ||
| Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease | Q46617730 | ||
| Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. | Q46672540 | ||
| Effects of atorvastatin on arterial endothelial function in coronary bypass surgery | Q46794365 | ||
| Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. | Q47804385 | ||
| A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? | Q48341274 | ||
| Cyclosporine inhibits endothelial cell prostacyclin production. | Q50888173 | ||
| Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. | Q52538187 | ||
| The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | Q54259738 | ||
| Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease | Q57252632 | ||
| Cyclosporine toxicity on cultured rat microvascular endothelial cells | Q69496648 | ||
| Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury | Q70191600 | ||
| Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation | Q72419264 | ||
| Toxicity of mitomycin C toward cultured pulmonary artery endothelium | Q72486557 | ||
| Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients | Q73215569 | ||
| Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease | Q73348876 | ||
| Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin | Q73416431 | ||
| Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody | Q74350027 | ||
| Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease | Q74372364 | ||
| Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications | Q74439558 | ||
| Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy | Q74523446 | ||
| Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase | Q77378371 | ||
| Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation | Q77962021 | ||
| Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO) | Q78094076 | ||
| Ultrastructural examination of glomerular and tubular changes in renal allografts with cyclosporine toxicity | Q79270431 | ||
| Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention | Q79351921 | ||
| Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes | Q80111836 | ||
| Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab | Q80155799 | ||
| Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | Q80177840 | ||
| Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q80252186 | ||
| Significance of elevation in cell-derived microparticles after allogeneic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP | Q81093825 | ||
| Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study | Q82582932 | ||
| Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation | Q83931969 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 709-719 | |
| P577 | publication date | 2007-07-02 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? | |
| P478 | volume | 40 |
| Q91838682 | A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD |
| Q26992169 | A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury |
| Q38726036 | Acute kidney injury in HCT: an update |
| Q34448474 | Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States |
| Q91713789 | Acute kidney injury in the patient with cancer |
| Q35200663 | Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complications |
| Q88101871 | Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells |
| Q41923053 | Central nervous system complications after allogeneic hematopoietic stem cell transplantation |
| Q33386036 | Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning |
| Q36492812 | Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat). |
| Q33415603 | Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults |
| Q33395998 | Do NK cells contribute to the pathophysiology of transplant-associated thrombotic microangiopathy? |
| Q33402385 | Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? |
| Q33391308 | Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. |
| Q44696198 | Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience. |
| Q52875784 | Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. |
| Q33412325 | Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. |
| Q34522746 | Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient |
| Q33393944 | Evaluation of schistocyte monitoring after haematopoietic stem cell transplantation |
| Q47163363 | Everolimus for pediatric patients with acute graft-versus-host disease after hematopoietic stem cell transplantation: A pilot study |
| Q33418635 | Fragmented Red Cell as a Possible Favorable Prognostic Marker of Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy. |
| Q48261069 | GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. |
| Q42265724 | Graft versus host disease-dependent renal dysfunction after hematopoietic stem cell transplantation |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q34122035 | Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis |
| Q33424902 | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy |
| Q28069228 | Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment |
| Q41992358 | Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. |
| Q33420858 | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition |
| Q81434702 | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder |
| Q62029355 | High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease |
| Q33409874 | Idiopathic pneumonia syndrome with thrombotic microangiopathy-related changes after allogeneic hematopoietic stem cell transplantation |
| Q89777302 | In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy |
| Q33421514 | Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. |
| Q38806679 | Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? |
| Q38132157 | Neurological complications of transplantation: part I: hematopoietic cell transplantation |
| Q38382457 | Onco-nephrology: current concepts and future perspectives |
| Q33417690 | Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant |
| Q40096407 | Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation |
| Q46774802 | Post-transplant TMA: still waiting |
| Q57917425 | Post-transplant endothelial disorder after hematopoietic SCT: a blinded autopsy study |
| Q33384578 | Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria |
| Q38902112 | Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation. |
| Q33420131 | Pretransplant-corrected QT dispersion as a predictor of pericardial effusion after pediatric hematopoietic stem cell transplantation |
| Q41685216 | Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q42200268 | Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation |
| Q33407913 | Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q33396969 | Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. |
| Q97557966 | Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT |
| Q33413498 | Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus |
| Q80813563 | Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura |
| Q40281926 | Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies |
| Q56529806 | Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide |
| Q33392710 | Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation |
| Q36862464 | The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate |
| Q33424153 | The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q38287610 | Therapeutic apheresis for patients with cancer |
| Q33394558 | Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center |
| Q33398627 | Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation. |
| Q33385836 | Thrombocytopenia and hemostatic disorders in chronic graft versus host disease |
| Q84873961 | Thrombotic microangiopathy |
| Q46476901 | Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma |
| Q33403897 | Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis |
| Q49375853 | Thrombotic microangiopathy following haematopoietic stem cell transplant |
| Q33383355 | Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment |
| Q38709053 | Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. |
| Q92087747 | Transplant-associated thrombotic microangiopathy: Diagnostic challenges and management strategies |
| Q33393068 | Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease |
| Q33386308 | Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange |
| Q33428744 | Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin |
| Q33408395 | Using rheopheresis for stem cell transplantation-associated thrombotic microangiopathy (TA-TMA). |
| Q90068152 | [Pulmonary arterial hypertension caused by graft-related thrombotic microangiopathy after ETP-ALL haplotype hematopoietic stem cell transplantation: a case report and literatures review] |
Search more.